Q2 Interim report: Work with the FDA application progressing as planned
“The results from two additional studies with DiviTum® will be presented at San Antonio Breast Cancer Symposium, the world's largest scientific conference on breast cancer”.- Anders Rylander, CEO of BiovicaPeriod: May-October 2019/2020 SEK 000s Q2 Q2 May-Oct 19/20 May-Oct 18/19 May-April 18/19 19/20 18/19Net sales 1,249 68 1,616 981 3,005Operating profit -5,990 -5,609 -12,087 -9,566 -21,718(loss)Profit (loss) for -5,958 -5,563 -12,026 -9,592